BRIEF-Gilead Sciences submits new drug application to U.S. FDA for Hepatitis C
December 08, 2016 at 08:58 AM EST
* Gilead Sciences Inc - nda for sof/vel/vox is based on data from two phase 3 studies (polaris-1 and polaris-4)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.